Agilent Technologies, Inc. A
172.79
(0.05)
(0.03%)
as of 25 Sep
- Market cap
- $49.0B
- P/E
- 33.9×
Follow A
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Agilent Technologies, Inc. (A) P/E ratio
As of 25 September 2026, Agilent Technologies, Inc. (A) trades at a P/E ratio of 33.9×. Over the past ten years it has ranged from 19.1× (May 2019) to 118× (January 2018); the current reading is higher than 62% of that period. That is in line with the Diagnostics & Research industry median of 33.9× and above the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 32.0× | 8.88% |
| FY2024 | 29.3× | 19.82% |
| FY2023 | 24.5× | (25.64%) |
| FY2022 | 32.9× | (16.53%) |
| FY2021 | 39.5× | (12.63%) |
| FY2020 | 45.2× | 102.14% |
| FY2019 | 22.3× | (65.51%) |
| FY2018 | 64.8× | 102.86% |
| FY2017 | 31.9× | 3.36% |
| FY2016 | 30.9× | (4.71%) |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jul 2026 | 27.2× | 17.40% |
| Apr 2026 | 23.2× | (22.35%) |
| Jan 2026 | 29.8× | (6.68%) |
| Oct 2025 | 32.0× | 19.13% |
| 43 more quarters | Free account |
Against its own ten years
Low 19.1×
High 118×
Ten-year median
32.4×
Current reading's percentile
62
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NTRA Natera, Inc. compare | n/m |
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 24.8× |
| IQV IQVIA Holdings Inc. compare | 33.3× |
| MTD Mettler-Toledo International, Inc. compare | 33.9× |
| A Agilent Technologies, Inc. | 33.9× |
| IDXX IDEXX Laboratories, Inc. compare | 36.2× |
| ILMN Illumina, Inc. compare | 50.4× |
| WAT Waters Corporation compare | 108× |
| Diagnostics & Research industry median | 33.9× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on A
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement